IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
MORGAN STANLEY (January 2009)
Key Figures for years ending December 31:
Unit: $ mil lions, ex cept EPS in $
2007 2008(E) 2009(E) 2010(E) 2011(E) 2012(E) 2013(E) 2014(E)
Sales 38,072 41,683 43,390 53,528 56,938 58,613 58,345 57,643
R&D 6,430 7,243 7,198 8,030 8,198 8,300 8,351 8,168
Pre-Tax Profit 7,487 9,828 10,861 12,092 13,873 14,549 14,090 13,838
Net Profit 6,518 8,391 9,063 9,548 10,952 11,454 11,010 10,721
EPS (continuing) 2.81 3.70 4.00 4.22 4.86 5.13 5.01 4.96
Sales of Key Products for years ending December 31:
Unit: $ mil lions
2007 2008(E) 2009(E) 2010(E) 2011(E) 2012(E) 2013(E) 2014(E)
Diovan 5,012 5,748 5,819 5,834 5,130 3,933 1,629 1,264
Exforge 102 431 676 775 874 874 593 230
Lotrel 748 376 182 146 116 93 75 67
Lescol 665 645 612 600 588 382 229 183
Tekturna/Diovan +
Tekturna FDC 40 159 291 387 449 493 514 532
Other Strategic 34 30 32 35 39 43 47 49
Mature Products 804 835 768 729 693 658 625 594
Cardiovascular 7,405 8,224 8,379 8,506 7,888 6,476 3,711 2,919
Glivec 3,050 3,688 3,902 4,234 4,441 4,655 4,864 4,973
Zometa 1,297 1,403 1,553 1,786 1,964 2,063 1,287 1,030
Sandostatin 1,027 1,139 1,142 1,024 929 857 802 380
Femara 937 1,136 1,238 1,362 1,409 774 619 508
Exjade 357 519 627 721 794 833 858 901
Other Oncology 283 249 234 227 220 214 207 201
Oncology 6,951 8,290 9,074 10,109 10,890 10,653 9,958 9,313
Trileptal 692 325 236 177 133 100 75 75
Exelon 632 812 841 891 936 749 599 479
Tegretol 413 464 427 405 385 366 348 330
Comtan/Stalevo 420 500 532 575 609 640 672 336
Ritalin 375 428 456 492 522 548 575 547
Other Strategic 382 600 604 622 640 660 679 645
Mature Products 431 421 367 330 297 268 241 217
CNS 3,345 3,550 3,562 3,643 3,722 3,579 3,488 2,928
Foradil 362 400 399 411 423 436 449 462
Xolair 140 204 217 243 256 256 256 256
TOBI 273 288 293 308 323 339 356 356
© 2009 IMS Health In cor po rated or its af fil i ates Page 116